GBGrzegorz Borowski

Grzegorz Borowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grzegorz Borowski has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Semaglutide as a promising treatment for metabolic dysfunction‑associated steatotic liver disease

    by Maria Zasadzińska, Grzegorz Borowski

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disorder globally, and if left untreated, it may progress to liver cirrhosis and even hepatocellular carcinoma. As of 2024, the European Association for the Study of the Liver Guidelines have recommended resmetirom as the only pharmacological treatment for adults with non-cirrhotic MASLD who have significant fibrosis (stage ≥2). However, lifestyle interventions and management of comorbidities, such as type 2 diabetes and obesity, remain the cornerstone of treatment. Glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown emerging promise in treating MASLD. Notably, the Phase III ESSENCE trial, presented in late 2024, demonstrated semaglutide's potential in improving liver fibrosis, confirmed through histological evaluation, marking a possible breakthrough for MASLD management. This review aims to synthesise current evidence on the efficacy of semaglutide in treating MASLD, highlighting its potential to fill a significant gap in the therapeutic options available for this growing global health concern.


  • Open Access

    Clinical characteristics and review of current treatment methods for trigeminal neuralgia

    by Grzegorz Borowski, Maria Zasadzińska, Adam Mróz, Julia Załęcka, Agnieszka Kluczna, Tomasz Dzierżanowski

    Trigeminal neuralgia is one of the most painful conditions a person can experience. Depending on the aetiology, 3 types of neuralgia can be distinguished: classic, secondary, and idiopathic. It can be a challenge in palliative care, especially in patients with multiple sclerosis, in whom...